First-in-human study of highly selective FGFR2 inhibitor, RLY-4008, in patients with intrahepatic cholangiocarcinoma and other advanced solid tumors.Alison M. Schram,Suneel Deepak Kamath,Anthony B. El-Khoueiry,Mitesh J. Borad,Kabir Mody,Amit Mahipal,Lipika Goyal,Vaibhav Sahai,Oleg Schmidt-Kittler,Jinshan Shen,Kai Yu Jen,Alicia Deary,Cori Ann Sherwin,Mahesh Padval,Beni B. Wolf,Vivek SubbiahAnnals of Oncology（2021）引用 10|浏览4暂无评分AI 理解论文溯源树样例生成溯源树，研究论文发展脉络Chat Paper正在生成论文摘要
